Skip to content
DataLookout
Menu

CARTITUDE-2NCT04133636

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 87 versions: 29 with changes below, 21 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 24 words
    • Secondary endpoints: details revised at 7 of 24 entries
    • Site details revised at 1 of 47 sites
  2. Notable Primary completion pushed from Aug 4, 2026 to Feb 26, 2027
    • Study completion moved earlier from Sep 3, 2029 to Aug 25, 2028
    v84
  3. Notable Primary endpoint(s) modified
    • Eligibility criteria expanded, about 9 words
    • Enrollment target: 210 to 208
    • Secondary endpoints: 23 to 24
    v83
  4. Minor Site details revised at 1 of 47 sitesv81
  5. Minor Study completion date: Jan 17, 2028 to Sep 3, 2029v79
Show 24 earlier versionsHide 24 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 237 to confirmed 210
    • Site details revised at 47 of 47 sites
    v78
  2. Minor Site details revised at 1 of 47 sitesv76
  3. Notable Primary completion date: Dec 1, 2025 to Aug 4, 2026
    • Study completion date: Nov 13, 2028 to Jan 17, 2028
    v74
  4. Minor Site details revised at 4 of 47 sitesv73
  5. Minor Site details revised at 1 of 47 sitesv68
  6. Minor Study sites: 46 to 47v65
  7. Minor Study sites: 44 to 46v63
  8. Minor Study sites: 42 to 44v61
  9. Minor Study sites: 41 to 42v60
  10. Minor Study sites: 39 to 41v59
  11. Minor Site details revised at 10 of 39 sitesv58
  12. Notable Trial status: Active, Not Recruiting to Recruiting
    • Enrollment target: 169 to 237
    • Study sites: 37 to 39
    v57
  13. Notable Primary completion date: May 30, 2025 to Dec 1, 2025
    • Study sites revised (37)
    v56
  14. Minor Study sites: 33 to 37v55
  15. Minor Study sites revised (33)v53
  16. Minor Study sites revised (33)v50
  17. Minor Study completion date: Jun 10, 2027 to Nov 13, 2028
    • Study sites revised (33)
    v49
  18. Minor Study completion date: May 30, 2025 to Jun 10, 2027
    • Site details revised at 1 of 33 sites
    v48
  19. Minor Site details revised at 1 of 33 sitesv44
  20. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 157 to confirmed 169
    • Site details revised at 33 of 33 sites
    v43
  21. Notable Primary completion date: Aug 1, 2024 to May 30, 2025
    • Site details revised at 28 of 33 sites
    v41
  22. Minor Study sites: 43 to 33v40
  23. Minor Study completion date: Feb 25, 2026 to May 30, 2025v39
  24. Minor Study sites revised (43)v38
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
Timeframe: At least 1 year after JNJ-68284528 infusion on Day 1
For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
Timeframe: At least 1 year after JNJ-68284528 infusion on Day 1

Secondary (24)

Overall Response Rate (ORR)
Cohorts A, B, C, D, E, and F: VGPR or Better Rate
Cohorts A, B, C, D, E, and F: Clinical Benefit Rate (CBR)
Duration of Response (DOR)
Time to Response (TTR)
Show 19 moreShow less
Cohorts A, B, C, D, E, and F: MRD Negative Rate at 12 Months for Participants who Achieve a Complete Response (CR)
Time to MRD Negativity
Duration of MRD Negativity
Cohorts A, B, C, D, E, and F: MRD Negative Rate Across Clinical Response
Number of Participants with Adverse Events by Severity
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
Number of Participants with Laboratory Abnormalities
Number of Participants with Vital Signs Abnormalities
Cohorts A, B, C, D, E, and F: Levels of B-Cell Maturation Antigen (BCMA) Expressing Cells and Soluble BCMA
Cohorts A, B, C, D, E, and F: Systemic Inflammatory Cytokine Concentrations
Cohorts A, B, C, D, E, and F: Levels of JNJ-68284528 T Cell Expansion (proliferation), and Persistence
Cohorts A, B, C, D, E, and F: Number of Participants with Anti-JNJ-68284528 Antibodies
For US sites only: Cohort G: Percentage of Participants with Complete Response (CR) or Better
For US sites only: Cohort G: Percentage of Participants with MRD-negative CR or sCR
For US sites only: Cohort G: Progression-free Survival on Next-line Therapy (PFS2)
For US sites only: Cohort G: Overall Survival (OS)
For US sites only: Cohort G: Progression-free Survival (PFS)
For US sites only: Cohort G: Number of Participants with Measurable Replication Competent Lentivirus (RCL) in Whole Blood
For US sites only: Cohort G: Time to Subsequent Anti-Myeloma Therapy

Arms and interventions

JNJ-68284528Experimental

Single group assignment-Post lymphodepletion, JNJ-68284528 single infusion given to Part A participants: Cohort A (Progressive disease post 1-3 prior lines of therapy), Cohort B (Early relapse post front-line), Cohort C(Relapsed/refractory multiple myeloma post PI, IMiD,anti-CD38,anti-BCMA therapy), Cohort D(Less than CR post ASCT front-line therapy, some participants will receive JNJ-68284528 then lenalidomide), Cohort F(Newly diagnosed multiple myeloma \[NDMM\], standard risk \[International Staging System Stage I/II\] and post initial therapy); Cohort E(NDMM,transplant not planned, high risk disease) will first receive quadruplet induction regimen of daratumumab, bortezomib, lenalidomide and dexamethasone(D-VRd) then lymphodepletion and JNJ-68284528 then consolidation regimen of lenalidomide. Enrollment is closed for Cohorts A,B,C,D,E and F. For US sites only: Part B:Cohort G (NDMM, transplant not planned) will receive daratumumab, lenalidomide and dexamethasone followed by cilta-cel.

Drugs: JNJ-68284528, Lenalidomide, Daratumumab, Bortezomib, Dexamethasone

Sites

47 sites in 8 countries

United States 33, France 3, Belgium 2, Germany 2, Israel 2, Netherlands 2, Spain 2, Saudi Arabia 1